

Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007

Mylan to Present at Merrill Lynch's Global Pharmaceutical Conference Feb. 5, 2008

PITTSBURGH, Feb. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarter and nine months ended Dec. 31, 2007. The Company also will provide an operational and integration update on Merck Generics, which the Company acquired on Oct. 2, 2007. The Company will release its financial results before the market opens.

The Company also announced that it will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference today, Feb. 5, at 11:40 a.m. ET. A copy of the Company's slide presentation will be available at www.mylan.com.

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325- 4814 for international callers. A replay, available for approximately eight days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Web site (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Inc. 02/05/2008 CONTACT: Kris King of Mylan Inc.+1-724-514-1800 Web site: http://www.mylan.com (MYL)